董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ryan Rhodes | 男 | President, Chief Executive Officer and Director | 56 | 31.24万美元 | 未持股 | 2018-04-26 |
| Gil Kliman | 男 | Director | 59 | 未披露 | 未持股 | 2018-04-26 |
| Craig Taylor | 男 | Director | 67 | 未披露 | 未持股 | 2018-04-26 |
| Shelley Thunen | 女 | Director | 65 | 1.41万美元 | 未持股 | 2018-04-26 |
| Jeffery Bird | 男 | Director | 57 | 未披露 | 未持股 | 2018-04-26 |
| Frederick Moll | 男 | Chairman and Director | 66 | 未披露 | 未持股 | 2018-04-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gregory Anderson | 男 | Vice President, Marketing | 57 | 未披露 | 未持股 | 2018-04-26 |
| Ryan Rhodes | 男 | President, Chief Executive Officer and Director | 56 | 31.24万美元 | 未持股 | 2018-04-26 |
| Gabriele Zingaretti | 男 | Chief Operations Officer | 43 | 28.93万美元 | 未持股 | 2018-04-26 |
| Mark Hair | 男 | Chief Financial Officer | 48 | 未披露 | 未持股 | 2018-04-26 |
| Chris Aronson | 男 | Vice President, Sales | 42 | 未披露 | 未持股 | 2018-04-26 |
董事简历
中英对照 | 中文 | 英文- Ryan Rhodes
-
Ryan Rhodes自2016年7月起担任我们的总裁兼首席执行官，自2016年7月起担任我们的董事会成员。Rhodes从2002年1月到2015年6月担任Intuitive Surgical Inc.（手术机器人市场领导者）多个职位，包括全球临床营销副总裁、全球营销高级主管和营销主管。在加入Intuitive Surgical Inc.之前，罗兹先生在强生公司公司Ethicon Inc.担任了11年多的销售、市场营销、专业教育和市场开发等多个管理职位。Rhodes先生拥有圣地亚哥州立大学（San Diego State University）公共管理学士学位。
Ryan Rhodes has served as our President and Chief Executive Officer since July 2016 and as a member of our board of directors since July 2016. From January 2002 to June 2015 Mr. Rhodes held a number of positions at Intuitive Surgical Inc., a market leader in surgical robotics, including Vice-President of World-Wide Clinical Marketing, Senior Director of World-Wide Marketing and Director of Marketing. Prior to Intuitive Surgical Inc., Mr. Rhodes spent over 11 years in various management positions in sales, marketing, professional education, and market development at Ethicon Inc., a Johnson & Johnson Company. Mr. Rhodes holds a B.A. in Public Administration from San Diego State University. - Ryan Rhodes自2016年7月起担任我们的总裁兼首席执行官，自2016年7月起担任我们的董事会成员。Rhodes从2002年1月到2015年6月担任Intuitive Surgical Inc.（手术机器人市场领导者）多个职位，包括全球临床营销副总裁、全球营销高级主管和营销主管。在加入Intuitive Surgical Inc.之前，罗兹先生在强生公司公司Ethicon Inc.担任了11年多的销售、市场营销、专业教育和市场开发等多个管理职位。Rhodes先生拥有圣地亚哥州立大学（San Diego State University）公共管理学士学位。
- Ryan Rhodes has served as our President and Chief Executive Officer since July 2016 and as a member of our board of directors since July 2016. From January 2002 to June 2015 Mr. Rhodes held a number of positions at Intuitive Surgical Inc., a market leader in surgical robotics, including Vice-President of World-Wide Clinical Marketing, Senior Director of World-Wide Marketing and Director of Marketing. Prior to Intuitive Surgical Inc., Mr. Rhodes spent over 11 years in various management positions in sales, marketing, professional education, and market development at Ethicon Inc., a Johnson & Johnson Company. Mr. Rhodes holds a B.A. in Public Administration from San Diego State University.
- Gil Kliman
-
Gil Kliman，医学博士自2007年7月以来一直担任我们的董事会成员。他是InterWest Partners公司的董事总经理，在那里他曾领导他们的医疗设备团队（1999年以来）。Kliman博士还是眼科商业会议Ophthalm Innovation Summit的联合创始人和联合主席。Kliman博士在Glaukos Corporation和几家私人生命科学公司的董事会任职。Kliman博士在哈佛大学（Harvard University）获得工商管理硕士学位，在宾夕法尼亚大学（University of Pennsylvania）获得工商管理硕士学位，在斯坦福大学（Stanford University）获得工商管理硕士学位。
Gil Kliman, M.D. has served as a member of our board of directors since July 2007. Dr. Kliman is Managing Director at InterWest Partners, where he has led their medical device team since 1999. Dr. Kliman is also the co-founder and co-chairman of the Ophthalmology Innovation Summit, an ophthalmology business conference. Dr. Kliman serves on the board of directors of Glaukos Corporation and several private life science companies. Dr. Kliman received a B.A. from Harvard University, an M.D. from the University of Pennsylvania and an M.B.A. from Stanford University. - Gil Kliman，医学博士自2007年7月以来一直担任我们的董事会成员。他是InterWest Partners公司的董事总经理，在那里他曾领导他们的医疗设备团队（1999年以来）。Kliman博士还是眼科商业会议Ophthalm Innovation Summit的联合创始人和联合主席。Kliman博士在Glaukos Corporation和几家私人生命科学公司的董事会任职。Kliman博士在哈佛大学（Harvard University）获得工商管理硕士学位，在宾夕法尼亚大学（University of Pennsylvania）获得工商管理硕士学位，在斯坦福大学（Stanford University）获得工商管理硕士学位。
- Gil Kliman, M.D. has served as a member of our board of directors since July 2007. Dr. Kliman is Managing Director at InterWest Partners, where he has led their medical device team since 1999. Dr. Kliman is also the co-founder and co-chairman of the Ophthalmology Innovation Summit, an ophthalmology business conference. Dr. Kliman serves on the board of directors of Glaukos Corporation and several private life science companies. Dr. Kliman received a B.A. from Harvard University, an M.D. from the University of Pennsylvania and an M.B.A. from Stanford University.
- Craig Taylor
-
Craig Taylor自2017年3月以来一直担任我们的董事会成员。他是Alloy Ventures公司（他于1996年共同创立的公司，在那里他专注于实验室仪器、诊断和医疗设备的投资）的总裁。他曾任职the MIT/Stanford Venture Laboratory的顾问委员会，也曾担任the National Venture Capital Association的董事。Taylor先生在布朗大学（Brown University）获得物理学学士学位和硕士学位，并在斯坦福大学（Stanford University）获得工商管理硕士学位。
Craig Taylor has served as a member of our board of directors since March 2017. Mr. Taylor is President of Alloy Ventures, Inc., which he co-founded in 1996 and where he focuses on investments in laboratory instrumentation, diagnostics and medical devices. He served on the Board of Advisors of the MIT/Stanford Venture Laboratory and served as a Director at the National Venture Capital Association. Mr. Taylor received a B.S. and an M.S. in physics from Brown University, as well as an M.B.A. from Stanford University. - Craig Taylor自2017年3月以来一直担任我们的董事会成员。他是Alloy Ventures公司（他于1996年共同创立的公司，在那里他专注于实验室仪器、诊断和医疗设备的投资）的总裁。他曾任职the MIT/Stanford Venture Laboratory的顾问委员会，也曾担任the National Venture Capital Association的董事。Taylor先生在布朗大学（Brown University）获得物理学学士学位和硕士学位，并在斯坦福大学（Stanford University）获得工商管理硕士学位。
- Craig Taylor has served as a member of our board of directors since March 2017. Mr. Taylor is President of Alloy Ventures, Inc., which he co-founded in 1996 and where he focuses on investments in laboratory instrumentation, diagnostics and medical devices. He served on the Board of Advisors of the MIT/Stanford Venture Laboratory and served as a Director at the National Venture Capital Association. Mr. Taylor received a B.S. and an M.S. in physics from Brown University, as well as an M.B.A. from Stanford University.
- Shelley Thunen
-
Shelley Thunen自2015年7月以来一直担任我们的董事会成员。Thunen女士自2016年1月起担任医疗器械公司RxSight，Inc.的首席行政官兼首席财务官。2013年1月至2015年10月，Thunen女士担任医疗设备公司Endologix Inc.的首席财务官兼公司秘书。2010年8月至2012年12月，Thunen女士担任Lensx，Inc.的副总经理，这是Alcon，Inc.的间接全资子公司，Alcon，Inc.是视力护理产品的开发商和制造商，Novartis International AG于2011年4月收购了该公司。2008年4月至2010年8月，Thunen女士担任Lensx，Inc.的董事会成员兼审计委员会主席，2009年11月至2010年8月，Thunen女士担任Lensx，Inc.的首席财务官兼Vice President，该公司于2010年8月被Alcon，Inc.收购。在Lensx，Inc.之前，Thunen女士在公共和私人医疗设备公司担任过各种管理和执行职务。Thunen女士在加州大学欧文分校（University of California，Irvine）获得经济学学士学位和工商管理硕士学位。
Shelley Thunen joined RxSight, Inc. in January 2016 as Chief Administrative Officer and has served as Chief Financial Officer since February 2017. From January 2013 to October 2015 Ms. Thunen served as the Chief Financial Officer of Endologix, Inc. From August 2010 to December 2012 Ms. Thunen served as Associate General Manager of Alcon LenSx, Inc. Prior to the Alcon acquisition of LenSx, Inc. in August 2010 she served as a board member and chair of the audit committee from April 2008 to August 2010 as well as Chief Financial Officer and Vice President, Operations from November 2009 to August 2010. Ms. Thunen joined IntraLase Corp. in May 2001 and was its Chief Financial Officer and later Executive Vice President & Chief Financial Officer until its acquisition by Advanced Medical Optics, Inc. in April 2007. Ms. Thunen served on the board of directors of eyeonics, Inc. from June 2007 to February 2008 and as a board member and chair of the audit committee of Restoration Robotics, Inc. Nasdaq: HAIR from July 2015 to November 2019 prior to its acquisition by Venus Concept Inc. (Nasdaq: VERO) She also has served as a board member and audit committee chair of Surface Ophthalmics, Inc since August 2020. Ms. Thunen received a B.A. in economics and an M.B.A. from the University of California, Irvine. - Shelley Thunen自2015年7月以来一直担任我们的董事会成员。Thunen女士自2016年1月起担任医疗器械公司RxSight，Inc.的首席行政官兼首席财务官。2013年1月至2015年10月，Thunen女士担任医疗设备公司Endologix Inc.的首席财务官兼公司秘书。2010年8月至2012年12月，Thunen女士担任Lensx，Inc.的副总经理，这是Alcon，Inc.的间接全资子公司，Alcon，Inc.是视力护理产品的开发商和制造商，Novartis International AG于2011年4月收购了该公司。2008年4月至2010年8月，Thunen女士担任Lensx，Inc.的董事会成员兼审计委员会主席，2009年11月至2010年8月，Thunen女士担任Lensx，Inc.的首席财务官兼Vice President，该公司于2010年8月被Alcon，Inc.收购。在Lensx，Inc.之前，Thunen女士在公共和私人医疗设备公司担任过各种管理和执行职务。Thunen女士在加州大学欧文分校（University of California，Irvine）获得经济学学士学位和工商管理硕士学位。
- Shelley Thunen joined RxSight, Inc. in January 2016 as Chief Administrative Officer and has served as Chief Financial Officer since February 2017. From January 2013 to October 2015 Ms. Thunen served as the Chief Financial Officer of Endologix, Inc. From August 2010 to December 2012 Ms. Thunen served as Associate General Manager of Alcon LenSx, Inc. Prior to the Alcon acquisition of LenSx, Inc. in August 2010 she served as a board member and chair of the audit committee from April 2008 to August 2010 as well as Chief Financial Officer and Vice President, Operations from November 2009 to August 2010. Ms. Thunen joined IntraLase Corp. in May 2001 and was its Chief Financial Officer and later Executive Vice President & Chief Financial Officer until its acquisition by Advanced Medical Optics, Inc. in April 2007. Ms. Thunen served on the board of directors of eyeonics, Inc. from June 2007 to February 2008 and as a board member and chair of the audit committee of Restoration Robotics, Inc. Nasdaq: HAIR from July 2015 to November 2019 prior to its acquisition by Venus Concept Inc. (Nasdaq: VERO) She also has served as a board member and audit committee chair of Surface Ophthalmics, Inc since August 2020. Ms. Thunen received a B.A. in economics and an M.B.A. from the University of California, Irvine.
- Jeffery Bird
-
Jeffery Bird，M.D.，Ph.D.自2005年7月起担任公司董事。自2003年7月以来，Bird博士一直担任Sutter Hill Ventures的常务董事，该公司是加利福尼亚州的一家有限合伙企业，他在该公司专注于梦百合，包括生物技术和医疗设备。Bird博士是PortolaPharmaceuticals，Inc.的董事会成员Bird博士此前曾担任Horizon Pharma plc（直到2015年10月）和Threshold Pharmaceuticals，Inc.（直到2017年8月）的董事会成员。Bird博士在斯坦福大学（Stanford University）获得生物科学学士学位、博士学位和医学博士学位。
Jeffery Bird, M.D., Ph.D. has served as a member of our board of directors since July 2005. Since July 2003 Dr. Bird has been a Managing Director at Sutter Hill Ventures, a California limited partnership “Sutter Hill Ventures”, where he focuses on healthcare, including biotechnology and medical devices. Dr. Bird serves on the board of directors of Portola Pharmaceuticals, Inc. Dr. Bird previously served on the boards of directors of Horizon Pharma plc until October 2015 and Threshold Pharmaceuticals, Inc. until August 2017. Dr. Bird received a B.S. in Biological Sciences, a Ph.D. and an M.D. from Stanford University. - Jeffery Bird，M.D.，Ph.D.自2005年7月起担任公司董事。自2003年7月以来，Bird博士一直担任Sutter Hill Ventures的常务董事，该公司是加利福尼亚州的一家有限合伙企业，他在该公司专注于梦百合，包括生物技术和医疗设备。Bird博士是PortolaPharmaceuticals，Inc.的董事会成员Bird博士此前曾担任Horizon Pharma plc（直到2015年10月）和Threshold Pharmaceuticals，Inc.（直到2017年8月）的董事会成员。Bird博士在斯坦福大学（Stanford University）获得生物科学学士学位、博士学位和医学博士学位。
- Jeffery Bird, M.D., Ph.D. has served as a member of our board of directors since July 2005. Since July 2003 Dr. Bird has been a Managing Director at Sutter Hill Ventures, a California limited partnership “Sutter Hill Ventures”, where he focuses on healthcare, including biotechnology and medical devices. Dr. Bird serves on the board of directors of Portola Pharmaceuticals, Inc. Dr. Bird previously served on the boards of directors of Horizon Pharma plc until October 2015 and Threshold Pharmaceuticals, Inc. until August 2017. Dr. Bird received a B.S. in Biological Sciences, a Ph.D. and an M.D. from Stanford University.
- Frederick Moll
-
Frederick Moll，医学博士自2002年11月以来一直是我们董事会的成员和主席。Moll博士也是联合创始人，自2012年9月起担任Auris Surgical Robotics，Inc.的首席执行官。从2002年到2010年，他曾担任Hansen Medical公司（医疗机器人公司，也是他共同创立的公司）的首席执行官。在此之前，Moll博士共同创立了直觉外科公司，并从1995年到2002年担任其第一任首席执行官。Moll博士还联合创立了Origin Medisystems，Inc.，该公司后来在被礼来公司（Eli Lilly&Co.）和EndoTherapeutics Corp.收购后成为Guidant Corp.的一家运营公司。Moll博士在Biolase，Inc.和Intersectent，Inc.的董事会任职。Moll博士在加州大学伯克利分校（University of California at Berkeley）获得经济学学士学位，在斯坦福大学（Stanford University）获得管理学硕士学位，在华盛顿大学（University of Washington）获得医学博士学位。
Frederick Moll, M.D. has been a member and served as Chairman of our board since November 2002. Dr. Moll is also a co-founder, and, since September 2012 is the Chief Executive Officer of Auris Surgical Robotics, Inc. From 2002 to 2010 Dr. Moll served as the Chief Executive Officer of Hansen Medical, a medical robotics company, which he also co-founded. Previously, Dr. Moll co-founded Intuitive Surgical, Inc. and from 1995 to 2002 served as its first Chief Executive Officer. Dr. Moll also co-founded Origin Medisystems, Inc., which later became an operating company within Guidant Corp. following its acquisition by Eli Lilly & Co., and Endotherapeutics Corp. Dr. Moll serves on the boards of directors of Biolase, Inc. and IntersectENT, Inc. Dr. Moll received a B.A. in economics from the University of California at Berkeley, an M.S. degree in management from Stanford University and an M.D. from the University of Washington. - Frederick Moll，医学博士自2002年11月以来一直是我们董事会的成员和主席。Moll博士也是联合创始人，自2012年9月起担任Auris Surgical Robotics，Inc.的首席执行官。从2002年到2010年，他曾担任Hansen Medical公司（医疗机器人公司，也是他共同创立的公司）的首席执行官。在此之前，Moll博士共同创立了直觉外科公司，并从1995年到2002年担任其第一任首席执行官。Moll博士还联合创立了Origin Medisystems，Inc.，该公司后来在被礼来公司（Eli Lilly&Co.）和EndoTherapeutics Corp.收购后成为Guidant Corp.的一家运营公司。Moll博士在Biolase，Inc.和Intersectent，Inc.的董事会任职。Moll博士在加州大学伯克利分校（University of California at Berkeley）获得经济学学士学位，在斯坦福大学（Stanford University）获得管理学硕士学位，在华盛顿大学（University of Washington）获得医学博士学位。
- Frederick Moll, M.D. has been a member and served as Chairman of our board since November 2002. Dr. Moll is also a co-founder, and, since September 2012 is the Chief Executive Officer of Auris Surgical Robotics, Inc. From 2002 to 2010 Dr. Moll served as the Chief Executive Officer of Hansen Medical, a medical robotics company, which he also co-founded. Previously, Dr. Moll co-founded Intuitive Surgical, Inc. and from 1995 to 2002 served as its first Chief Executive Officer. Dr. Moll also co-founded Origin Medisystems, Inc., which later became an operating company within Guidant Corp. following its acquisition by Eli Lilly & Co., and Endotherapeutics Corp. Dr. Moll serves on the boards of directors of Biolase, Inc. and IntersectENT, Inc. Dr. Moll received a B.A. in economics from the University of California at Berkeley, an M.S. degree in management from Stanford University and an M.D. from the University of Washington.
高管简历
中英对照 | 中文 | 英文- Gregory Anderson
Gregory Anderson自2017年9月以来一直担任我们的市场开发Vice President。从2013年8月到2017年4月，安德森先生担任雅培医疗光学公司（Abbott Medical Optics Inc.）（雅培公司的一个部门）的美国销售总监，雅培是一家视力和眼睛梦百合公司，现在是一家强生公司公司强生公司Vision。Anderson从2007年6月到2013年8月担任OptiMedica Corp.（一家风险投资公司，专注于使用激光技术进行白内障手术，直到被Abbott收购）销售Vice President。Anderson从2005年12月到2007年6月担任Intralase Inc.（一家开发激光眼科手术技术的公司）销售Vice President。Anderson先生在马里兰大学（University of Maryland）获得营销学学士学位。
Gregory Anderson has served as our Vice President of Market Development since September 2017. From August 2013 to April 2017 Mr. Anderson was the Director of US Sales for Abbott Medical Optics Inc., a division of Abbott Laboratories, or Abbott, a vision and eye healthcare company, now Johnson & Johnson Vision, a Johnson & Johnson Company. From June 2007 to August 2013 Mr. Anderson was the Vice President of Sales at OptiMedica Corp., a venture-funded company focused on cataract surgery using laser technology until it was acquired by Abbott. From December 2005 to June 2007 Mr. Anderson was the Vice President of Sales at IntraLase Inc., a company that developed laser eye surgery technologies. Mr. Anderson has a B.S. in Marketing from the University of Maryland.- Gregory Anderson自2017年9月以来一直担任我们的市场开发Vice President。从2013年8月到2017年4月，安德森先生担任雅培医疗光学公司（Abbott Medical Optics Inc.）（雅培公司的一个部门）的美国销售总监，雅培是一家视力和眼睛梦百合公司，现在是一家强生公司公司强生公司Vision。Anderson从2007年6月到2013年8月担任OptiMedica Corp.（一家风险投资公司，专注于使用激光技术进行白内障手术，直到被Abbott收购）销售Vice President。Anderson从2005年12月到2007年6月担任Intralase Inc.（一家开发激光眼科手术技术的公司）销售Vice President。Anderson先生在马里兰大学（University of Maryland）获得营销学学士学位。
- Gregory Anderson has served as our Vice President of Market Development since September 2017. From August 2013 to April 2017 Mr. Anderson was the Director of US Sales for Abbott Medical Optics Inc., a division of Abbott Laboratories, or Abbott, a vision and eye healthcare company, now Johnson & Johnson Vision, a Johnson & Johnson Company. From June 2007 to August 2013 Mr. Anderson was the Vice President of Sales at OptiMedica Corp., a venture-funded company focused on cataract surgery using laser technology until it was acquired by Abbott. From December 2005 to June 2007 Mr. Anderson was the Vice President of Sales at IntraLase Inc., a company that developed laser eye surgery technologies. Mr. Anderson has a B.S. in Marketing from the University of Maryland.
- Ryan Rhodes
Ryan Rhodes自2016年7月起担任我们的总裁兼首席执行官，自2016年7月起担任我们的董事会成员。Rhodes从2002年1月到2015年6月担任Intuitive Surgical Inc.（手术机器人市场领导者）多个职位，包括全球临床营销副总裁、全球营销高级主管和营销主管。在加入Intuitive Surgical Inc.之前，罗兹先生在强生公司公司Ethicon Inc.担任了11年多的销售、市场营销、专业教育和市场开发等多个管理职位。Rhodes先生拥有圣地亚哥州立大学（San Diego State University）公共管理学士学位。
Ryan Rhodes has served as our President and Chief Executive Officer since July 2016 and as a member of our board of directors since July 2016. From January 2002 to June 2015 Mr. Rhodes held a number of positions at Intuitive Surgical Inc., a market leader in surgical robotics, including Vice-President of World-Wide Clinical Marketing, Senior Director of World-Wide Marketing and Director of Marketing. Prior to Intuitive Surgical Inc., Mr. Rhodes spent over 11 years in various management positions in sales, marketing, professional education, and market development at Ethicon Inc., a Johnson & Johnson Company. Mr. Rhodes holds a B.A. in Public Administration from San Diego State University.- Ryan Rhodes自2016年7月起担任我们的总裁兼首席执行官，自2016年7月起担任我们的董事会成员。Rhodes从2002年1月到2015年6月担任Intuitive Surgical Inc.（手术机器人市场领导者）多个职位，包括全球临床营销副总裁、全球营销高级主管和营销主管。在加入Intuitive Surgical Inc.之前，罗兹先生在强生公司公司Ethicon Inc.担任了11年多的销售、市场营销、专业教育和市场开发等多个管理职位。Rhodes先生拥有圣地亚哥州立大学（San Diego State University）公共管理学士学位。
- Ryan Rhodes has served as our President and Chief Executive Officer since July 2016 and as a member of our board of directors since July 2016. From January 2002 to June 2015 Mr. Rhodes held a number of positions at Intuitive Surgical Inc., a market leader in surgical robotics, including Vice-President of World-Wide Clinical Marketing, Senior Director of World-Wide Marketing and Director of Marketing. Prior to Intuitive Surgical Inc., Mr. Rhodes spent over 11 years in various management positions in sales, marketing, professional education, and market development at Ethicon Inc., a Johnson & Johnson Company. Mr. Rhodes holds a B.A. in Public Administration from San Diego State University.
- Gabriele Zingaretti
Gabriele Zingaretti自2016年2月起担任我们的首席运营官。在此之前，Zingaretti博士于2008年至2012年9月担任我们的高级软件工程师，于2012年9月至2013年3月担任我们的Vice President之一，并于2013年至2016年2月担任我们的研发副总裁。从2000年到2007年，Zingaretti博士在R2Technology，Inc.开发了检测乳腺癌的先进算法。从2007年到2008年，Zingaretti博士在蛋白质组学集团Thermo Fisher Scientific担任软件架构师。Zingaretti博士在罗马大学（University of Rome）获得生物医学工程博士学位，并参加了哥伦比亚大学（Columbia University）肥胖研究中心为期两年的博士后研究金。Zingaretti博士在意大利比萨的ITC Antonio Pacinotti获得学士学位。
Gabriele Zingaretti has served as our Chief Operations Officer since February 2016. Prior thereto, from 2008 to September 2012 Dr. Zingaretti served as our Senior Software Engineer, from September 2012 to March 2013 as one of our Vice Presidents and from 2013 until February 2016 as our Vice President of Research & Development. From 2000 to 2007 Dr. Zingaretti developed advanced algorithms for detecting breast cancer at R2 Technology, Inc. From 2007 to 2008 Dr. Zingaretti worked as Software Architect for Thermo Fisher Scientific in the proteomics group. Dr. Zingaretti received his doctorate in Biomedical Engineering from the University of Rome and participated in a two-year postdoctoral research fellowship at the Obesity Research Center at Columbia University. Dr. Zingaretti received his bachelor’s degree from ITC Antonio Pacinotti in Pisa, Italy.- Gabriele Zingaretti自2016年2月起担任我们的首席运营官。在此之前，Zingaretti博士于2008年至2012年9月担任我们的高级软件工程师，于2012年9月至2013年3月担任我们的Vice President之一，并于2013年至2016年2月担任我们的研发副总裁。从2000年到2007年，Zingaretti博士在R2Technology，Inc.开发了检测乳腺癌的先进算法。从2007年到2008年，Zingaretti博士在蛋白质组学集团Thermo Fisher Scientific担任软件架构师。Zingaretti博士在罗马大学（University of Rome）获得生物医学工程博士学位，并参加了哥伦比亚大学（Columbia University）肥胖研究中心为期两年的博士后研究金。Zingaretti博士在意大利比萨的ITC Antonio Pacinotti获得学士学位。
- Gabriele Zingaretti has served as our Chief Operations Officer since February 2016. Prior thereto, from 2008 to September 2012 Dr. Zingaretti served as our Senior Software Engineer, from September 2012 to March 2013 as one of our Vice Presidents and from 2013 until February 2016 as our Vice President of Research & Development. From 2000 to 2007 Dr. Zingaretti developed advanced algorithms for detecting breast cancer at R2 Technology, Inc. From 2007 to 2008 Dr. Zingaretti worked as Software Architect for Thermo Fisher Scientific in the proteomics group. Dr. Zingaretti received his doctorate in Biomedical Engineering from the University of Rome and participated in a two-year postdoctoral research fellowship at the Obesity Research Center at Columbia University. Dr. Zingaretti received his bachelor’s degree from ITC Antonio Pacinotti in Pisa, Italy.
- Mark Hair
Mark Hair自2018年1月起担任我们的首席财务官。Hair先生最近于2017年4月至2017年8月担任Allergan plc的首席会计官，并于2016年5月至2017年4月担任被Allergan plc收购的ZELTIQAesthetics，Inc.的首席会计官。在Zeltiq时，Hair先生负责管理组织的会计职能，监督技术会计事项和公共报告义务，并实施Sarbanes Oxley合规计划。Hair先生在2016年1月至2016年5月担任Accuray Inc.财务Vice President期间也扮演了类似的角色。从2015年10月到2016年1月，Hair先生是St.Jude Medical的独立承包商，该公司购买了Thoratec Corporation，在此之前，从2015年9月到2016年1月，Hair先生是Thoratec Corporation的Vice President兼公司财务总监。2012年5月至2012年8月，Hair先生在DiamondFoods，Inc.担任高级副总裁财务和公司财务总监期间也发挥了类似的作用。在加入DiamondFoods，Inc.之前，Hair先生在Stoneturn Group，LLP（一家金融咨询精品店）和Deloitte LLP担任越来越重要的职务。Hair先生拥有杨百翰大学（Brigham Young University）会计学学士学位和会计学硕士学位。
Mark Hair has served as our Chief Financial Officer since January 2018. Mr. Hair most recently served as Chief Accounting Officer at Allergan plc from April 2017 to August 2017 and at ZELTIQ Aesthetics, Inc., which was acquired by Allergan plc, from May 2016 to April 2017. While at ZELTIQ, Mr. Hair was responsible for managing the organization’s accounting functions, overseeing technical accounting matters and public reporting obligations, and implementing a Sarbanes Oxley compliance program. Mr. Hair performed a similar role from January 2016 until May 2016 when he was Vice President of Finance at Accuray Inc. From October 2015 until January 2016 Mr. Hair was an independent contractor for St. Jude Medical, which purchased Thoratec Corporation, and prior to that, from September 2015 until January 2016 Mr. Hair was the Vice President and Corporate Controller at Thoratec Corporation. From May 2012 to August 2012 Mr. Hair performed a similar role while he was the Senior Vice President Finance and Corporate Controller at Diamond Foods, Inc. Before joining Diamond Foods, Inc., Mr. Hair held positions of increasing responsibility at StoneTurn Group, LLP, a financial consulting boutique and Deloitte LLP. Mr. Hair holds a B.S. in accounting and a Master of Accountancy from Brigham Young University.- Mark Hair自2018年1月起担任我们的首席财务官。Hair先生最近于2017年4月至2017年8月担任Allergan plc的首席会计官，并于2016年5月至2017年4月担任被Allergan plc收购的ZELTIQAesthetics，Inc.的首席会计官。在Zeltiq时，Hair先生负责管理组织的会计职能，监督技术会计事项和公共报告义务，并实施Sarbanes Oxley合规计划。Hair先生在2016年1月至2016年5月担任Accuray Inc.财务Vice President期间也扮演了类似的角色。从2015年10月到2016年1月，Hair先生是St.Jude Medical的独立承包商，该公司购买了Thoratec Corporation，在此之前，从2015年9月到2016年1月，Hair先生是Thoratec Corporation的Vice President兼公司财务总监。2012年5月至2012年8月，Hair先生在DiamondFoods，Inc.担任高级副总裁财务和公司财务总监期间也发挥了类似的作用。在加入DiamondFoods，Inc.之前，Hair先生在Stoneturn Group，LLP（一家金融咨询精品店）和Deloitte LLP担任越来越重要的职务。Hair先生拥有杨百翰大学（Brigham Young University）会计学学士学位和会计学硕士学位。
- Mark Hair has served as our Chief Financial Officer since January 2018. Mr. Hair most recently served as Chief Accounting Officer at Allergan plc from April 2017 to August 2017 and at ZELTIQ Aesthetics, Inc., which was acquired by Allergan plc, from May 2016 to April 2017. While at ZELTIQ, Mr. Hair was responsible for managing the organization’s accounting functions, overseeing technical accounting matters and public reporting obligations, and implementing a Sarbanes Oxley compliance program. Mr. Hair performed a similar role from January 2016 until May 2016 when he was Vice President of Finance at Accuray Inc. From October 2015 until January 2016 Mr. Hair was an independent contractor for St. Jude Medical, which purchased Thoratec Corporation, and prior to that, from September 2015 until January 2016 Mr. Hair was the Vice President and Corporate Controller at Thoratec Corporation. From May 2012 to August 2012 Mr. Hair performed a similar role while he was the Senior Vice President Finance and Corporate Controller at Diamond Foods, Inc. Before joining Diamond Foods, Inc., Mr. Hair held positions of increasing responsibility at StoneTurn Group, LLP, a financial consulting boutique and Deloitte LLP. Mr. Hair holds a B.S. in accounting and a Master of Accountancy from Brigham Young University.
- Chris Aronson
Chris Aronson自2018年2月起担任我们的销售Vice President。从2004年到2018年，阿隆森先生领导开发和执行了新颖的上市战略和产品发布，同时优化了产品定位，销售增长，利用率和客户满意度，将其作为Cynosure，Inc.北美销售的高级副总裁，激光美容行业广泛的医疗器械系统的领先开发商和制造商。在加入Cynosure之前，Aronson先生曾担任史赛克公司的运动医学专家。Aronson先生拥有乔治梅森大学（George Mason University）文学学士学位。
Chris Aronson has served as our Vice President of Sales since February 2018. From 2004 to 2018 Mr. Aronson led the development and execution of novel go-to-market strategies and product launches while optimizing product positioning, sales growth, utilization and customer satisfaction as Senior Vice President of Sales, North America, at Cynosure, Inc., a leading developer and manufacture of a broad array of medical device systems in the laser aesthetic industry. Prior to Cynosure, Mr. Aronson served as a Sports Medicine Specialist at Stryker Corporation. Mr. Aronson has Bachelor of Arts from George Mason University.- Chris Aronson自2018年2月起担任我们的销售Vice President。从2004年到2018年，阿隆森先生领导开发和执行了新颖的上市战略和产品发布，同时优化了产品定位，销售增长，利用率和客户满意度，将其作为Cynosure，Inc.北美销售的高级副总裁，激光美容行业广泛的医疗器械系统的领先开发商和制造商。在加入Cynosure之前，Aronson先生曾担任史赛克公司的运动医学专家。Aronson先生拥有乔治梅森大学（George Mason University）文学学士学位。
- Chris Aronson has served as our Vice President of Sales since February 2018. From 2004 to 2018 Mr. Aronson led the development and execution of novel go-to-market strategies and product launches while optimizing product positioning, sales growth, utilization and customer satisfaction as Senior Vice President of Sales, North America, at Cynosure, Inc., a leading developer and manufacture of a broad array of medical device systems in the laser aesthetic industry. Prior to Cynosure, Mr. Aronson served as a Sports Medicine Specialist at Stryker Corporation. Mr. Aronson has Bachelor of Arts from George Mason University.